Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the Wisconsin facility could begin by the end of 2025.

“We celebrate this new growth milestone for MGS, which further strengthens our offer of unparalleled tooling capacity to ensure the seamless launch of large-scale programs. Our expanding global footprint continues to provide healthcare innovators with end-to-end support for new product introductions and ongoing production,” said Paul Manley, president and CEO of MGS. “MGS and Winther Mould share a strong customer focus and commitment to agility and reliability. Together, we are poised to deliver unmatched value, precision, and dedication to our global customers to accelerate the development of innovations that improve lives,” said Manley.

MGS Mfg. Group Inc., a global supplier of end-to-end manufacturing services to the healthcare industry, has acquired Danish tooling manufacturer Winther Mould Technology A/S. The investment in additional tooling capacity and expertise continues its strategic growth as a leading provider of high-precision plastic solutions for pharmaceutical, diagnostic, and medtech applications, said MGS in the announcement dated Oct. 2, 2023.

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus.

“We are excited Lilly is continuing our family’s mission of providing lifesaving medications to those who need them most. This milestone is a testament to the dedication of our Nexus employees in building a best-in-class injectable manufacturing facility,” Usman Ahmed, Nexus president and CEO said. “The combination of our teams and infrastructure with Lilly’s global platform will benefit patients all over the world.”

The Pleasant Prairie facility doesn’t provide contract manufacturing services, Lilly said. This allows for the sole dedication of the plant to Lilly’s manufacturing efforts geared toward injectable medicines.

Winther Mould brings 56 years of experience in design for manufacturing (DFM), mold design and manufacturing, and testing and validation to the MGS portfolio. In partnering with Winther Mould, MGS said it will add complex, premium-quality tooling and moldmaking capacity and expertise to its international network of tooling, automation, and manufacturing capabilities. MGS currently operates from 12 locations in the United States, Mexico, Ireland, Sweden, Germany and Denmark.

It’s the second acquisition of a Danish company by MGS this year. In June, it brought Technolution under its wing, a consultancy that provides R&D, regulatory compliance, quality, and project management assistance to companies in the pharma and medtech sectors.

Copyright © 2024 · WTWH Media LLC and its licensors. All rights reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

“The acquisition of this state-of-the-art facility underscores our unwavering commitment to growth and innovation, and we look forward to welcoming talented new Nexus colleagues to Lilly from the Pleasant Prairie facility,” said Edgardo Hernandez, EVP and president, Lilly Manufacturing. “We are investing boldly to serve our patients, to meet product demand and to build capabilities for our robust pipeline of the future.”